) A major role of the Cytogenetics Core will be to establish a cytogenetic profile for all acute lymphoblastic leukemias (ALL) studied by the project group. The """"""""entry point"""""""" cytogenetic profile, for all patients enrolled in clinical studies, will include fluorescence in situ hybridization (FISH) determination of t(9;22) [BCR-ABL]; t(12;21) [TEL-AML1]; 11q23 rearrangement [MLL]; t(1;19) [E2A-PBX1], 6q21 deletion, 9p21 deletion; and 12p13 deletion. These FISH characterizations will serve as the basis for correlations with patient outcome in Projects 10 and 4. The prognostic relevance of individual chromosomal aberrations, and of the cytogenetic profile, will be evaluated in the context of the various clinical studies. The """"""""entry point"""""""" FISH characterizations will also provide key reference points for the biology-oriented projects. Namely, the FISH evaluations will establish genomic correlates for ALL gene expression patterns (Project 8), and will identify subsets of ALL with 11q23 (MLL) rearrangements (Project 6), 6q, 9p and 12p13 deletions (Project 7), and TEL-AML1 fusions (Project 5). Another function of the core will be provision of an interactive molecular cytogenetic infrastructure for the program. To this end, the core will use molecular cytogenetic assays, including FISH, M-FISH, and comparative genomic hybridization (CGH) to evaluate genomic mechanisms for altered gene or protein expression. Routine clinical karyotyping will not be a function of the core. However, the core will be responsible for centralized review of leukemia karyotypes obtained for all study patients. In addition, the core will perform adjunct molecular cytogenetic evaluations, including unique-sequence FISH, chromosome painting/M-FISH, and CGH, in cases where the external karyotyping studies are ambiguous.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA068484-06
Application #
6405590
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1995-09-30
Project End
2005-04-30
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Bansal, Neha; Barach, Paul; Amdani, Shahnawaz M et al. (2018) When is early septal myectomy in children with hypertrophic cardiomyopathy justified? Transl Pediatr 7:362-366
Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945
Lipshultz, Steven E (2018) Letter by Lipshultz Regarding Article, ""Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"" Circ Res 122:e62-e63
Temple, Jennifer L; Bernard, Christophe; Lipshultz, Steven E et al. (2017) The Safety of Ingested Caffeine: A Comprehensive Review. Front Psychiatry 8:80
Rahman, Sunniyat; Magnussen, Michael; León, Theresa E et al. (2017) Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood 129:3221-3226
Hutchins, Kelley K; Siddeek, Hani; Franco, Vivian I et al. (2017) Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol 83:455-465
Bona, Kira; Blonquist, Traci M; Neuberg, Donna S et al. (2016) Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). Pediatr Blood Cancer 63:1012-8
Seftel, Matthew D; Neuberg, Donna; Zhang, Mei-Jie et al. (2016) Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol 91:322-9
Fraser, Raphael André; Lipsitz, Stuart R; Sinha, Debajyoti et al. (2016) Approximate median regression for complex survey data with skewed response. Biometrics 72:1336-1347
Lipshultz, Steven E; Anderson, Lynn M; Miller, Tracie L et al. (2016) Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer 122:946-53

Showing the most recent 10 out of 214 publications